A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Olympus Announces Plan to Establish Digital Excellence Centers Following Acquisition of Cloud-AI Endoscopy Startup Odin Vision

Olympus, a global MedTech company committed to making people’s lives healthier, safer and more fulfilling, announced the plan to establish a series of Digital Excellence Centers (DECs) following acquisition of London-based Odin Vision, a cloud-AI endoscopy company with a strong portfolio of commercially available computer-aided detection/diagnostic solutions and innovation pipeline of cloud-enabled applications.

The acquisition has strengthened Olympus’ recently announced strategy and initiatives in digital health and brings the promise of AI-powered real-time diagnosis and minimally invasive treatment of chronic diseases closer to reality, ultimately raising the standard of care across multiple medical specialties and improving patient outcomes.

Envisioning an intelligent endoscopy ecosystem for the benefit of patients and healthcare providers

Odin Vision is contributing to Olympus’ vision of the future of endoscopy. Combining the strength of its core endoscopy portfolio with innovative digital solutions, Olympus plans to collect and analyze procedural, clinical and medical device data in real time, and then, powered by a new, modern digital platform leveraging the latest AI algorithms and software, provide healthcare professionals with clinical and operational solutions designed to reduce administrative and cognitive burdens while also improving operational efficiency. These advancements will support healthcare institutions as they endeavor to raise their level of care.

“As a leader in endoscopy and innovator in the space, Olympus is passionate about delivering the next generation of intelligent integrated solutions and insights to healthcare providers,” said Shawn LaRocco, Global VP Customer Solutions, responsible for the digital health business at Olympus. “However, we cannot do it alone and are continuously looking to partner with other pioneers like Odin Vision who share this passion.”

Digital Excellence Centers to push the envelope of creative innovation

To enable this commercial strategy, Olympus plans to develop and establish DECs for the development of digital solutions around the world, beginning in London where the acquisition of Odin Vision has laid the groundwork. In addition to its portfolio, Odin Vision brings renowned AI and software expertise and development capabilities that synergize and further accelerate Olympus’ digital health strategy. DECs are to be located at current Olympus R&D sites in Hamburg, Boston and Tokyo, with the possibility of expanding to Silicon Valley and Tel Aviv at a later stage.

Peter Mountney, Ph.D., CEO of Odin Vision commented, “We are excited to set the stage for future innovation development by leading Olympus’ plans for the first DECs, all in the pursuit of empowering clinicians to deliver the best possible care and outcomes to patients using the latest digital and AI tools.”

“As Olympus looks to expand development capabilities in digital solutions, establishing DECs around the globe will allow us to access critical talent and to develop partnerships with start-ups and other companies who, like Odin Vision, are pushing the envelope of creative innovation,” said Karsten Klose, Global Head of Digital at Olympus.

Olympus and Odin Vision at HIMSS23

Olympus and Odin Vision will be at HIMSS23 European Healthcare Conference & Exhibition, from June 7 to 9, in Lisbon, Portugal.

– On stage: Olympus and Odin Vision will be on stage from 11:00-11:50 on Friday, June 8, at the center stage in the Centro de Congressos de Lisboa. They will discuss how digital solutions like Odin Vision’s are being integrated into patient care, leading to better outcomes.
– In the exhibition: Olympus will be present at the congress on June 8 and 9 can be found in Booth 826.

SourceOlympus
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy